Agios Pharmaceuticals Inc (AGIO) Expected to Post Earnings of -$1.65 Per Share
Analysts forecast that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will announce earnings per share (EPS) of ($1.65) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Agios Pharmaceuticals’ earnings, with estimates ranging from ($1.75) to ($1.51). Agios Pharmaceuticals reported earnings of ($1.34) per share in the same quarter last year, which indicates a negative year over year growth rate of 23.1%. The business is expected to issue its next quarterly earnings report on Thursday, February 15th.
According to Zacks, analysts expect that Agios Pharmaceuticals will report full year earnings of ($6.59) per share for the current fiscal year, with EPS estimates ranging from ($6.69) to ($6.44). For the next financial year, analysts anticipate that the firm will post earnings of ($6.68) per share, with EPS estimates ranging from ($7.22) to ($5.84). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Agios Pharmaceuticals.
Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, beating the consensus estimate of ($1.78) by $0.19. The firm had revenue of $11.35 million for the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. The company’s revenue was up 26.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.63) EPS.
Shares of Agios Pharmaceuticals (NASDAQ:AGIO) traded down $6.31 during trading on Wednesday, reaching $68.80. The company had a trading volume of 1,175,800 shares, compared to its average volume of 710,070. Agios Pharmaceuticals has a one year low of $39.24 and a one year high of $76.02. The company has a market cap of $3,420.00, a PE ratio of -10.97 and a beta of 1.83.
In other Agios Pharmaceuticals news, CEO David P. Schenkein sold 53,000 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $73.16, for a total transaction of $3,877,480.00. Following the sale, the chief executive officer now directly owns 53,000 shares of the company’s stock, valued at $3,877,480. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Scott Biller sold 2,146 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $62.69, for a total value of $134,532.74. The disclosure for this sale can be found here. Over the last three months, insiders have sold 80,130 shares of company stock worth $5,561,250. Insiders own 5.43% of the company’s stock.
Large investors have recently bought and sold shares of the business. QS Investors LLC purchased a new position in shares of Agios Pharmaceuticals during the second quarter valued at about $144,000. Cubist Systematic Strategies LLC grew its position in shares of Agios Pharmaceuticals by 1,041.0% during the second quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 3,123 shares in the last quarter. Bank of Montreal Can grew its position in shares of Agios Pharmaceuticals by 74.8% during the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 1,520 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in shares of Agios Pharmaceuticals during the third quarter valued at about $225,000. Finally, S&CO Inc. purchased a new position in shares of Agios Pharmaceuticals during the third quarter valued at about $227,000. 94.32% of the stock is currently owned by institutional investors and hedge funds.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.